Invivyd (NASDAQ:IVVD) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Invivyd (NASDAQ:IVVD) posted its quarterly earnings data on Thursday. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.10, Zacks reports.

Invivyd Stock Up 19.0 %

Shares of Invivyd stock traded up $0.14 on Thursday, hitting $0.86. 1,274,015 shares of the company traded hands, compared to its average volume of 4,203,471. Invivyd has a 12-month low of $0.35 and a 12-month high of $4.74. The company has a market cap of $102.51 million, a PE ratio of -0.45 and a beta of 0.09. The company has a 50-day moving average price of $0.97 and a 200 day moving average price of $0.87.

Analyst Ratings Changes

IVVD has been the subject of several recent research reports. D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Invivyd in a research note on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Invivyd in a research report on Monday, February 24th. Finally, Morgan Stanley decreased their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $7.89.

Insider Buying and Selling

In other Invivyd news, Director Terrance Mcguire sold 75,776 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $0.45, for a total value of $34,099.20. Following the transaction, the director now directly owns 3,492,498 shares of the company’s stock, valued at $1,571,624.10. This represents a 2.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders sold 365,943 shares of company stock worth $171,220. Corporate insiders own 17.90% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.